AGŐćČ˹ٷ˝

STOCK TITAN

Incyte Corp SEC Filings

INCY NASDAQ

Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Incyte’s latest 10-K means sifting through pages of clinical-trial data, FDA milestones, and royalty tables—details that can obscure crucial signals like how much Jakafi revenue offsets soaring R&D costs. If finding Incyte insider trading Form 4 transactions before a pivotal read-out feels daunting, you’re not alone.

Stock Titan’s AI reads every Incyte quarterly earnings report 10-Q filing, 8-K material events explained, and the full Incyte annual report 10-K simplified so you don’t have to. Our platform delivers real-time alerts the moment an Incyte Form 4 insider transactions real-time notice posts to EDGAR, then translates legal jargon into plain English. Need a quick brief on trial spend vs. cash reserves? Our AI-powered summaries surface it in one click, making understanding Incyte SEC documents with AI part of your routine.

Use the filing types below to answer the questions professionals ask every quarter:

  • 10-Q: Track segment revenue, pipeline spend, and compare results with our Incyte earnings report filing analysis.
  • 10-K: Review patent cliffs, market-size assumptions, and risk factorsâ€�Incyte SEC filings explained simply.
  • Form 4: Monitor Incyte executive stock transactions Form 4 for buying or selling patterns.
  • DEF 14A: See the Incyte proxy statement executive compensation section without hunting through tables.
  • 8-K: Get Incyte 8-K material events explained within minutes of release.

Whether you’re gauging partnership royalty streams or confirming cash runway, Stock Titan turns dense biotech disclosures into actionable knowledge—before the market reacts.

Rhea-AI Summary

Enhabit, Inc. (EHAB) â€� Form 4 insider transaction

Chief Human Resources Officer Tanya Renee Marion reported a single transaction dated 1 July 2025. Under transaction code F (shares withheld by the issuer to satisfy tax obligations upon vesting), 1,983 common shares were disposed of at an average price of $7.88 per share. Following the withholding, the executive’s direct beneficial ownership stands at 57,651 common shares. No derivative securities were reported, and the filing was signed on 2 July 2025.

The transaction represents routine tax-related share withholding rather than an open-market sale, so it does not materially alter the insider’s economic exposure or signal a change in conviction. The filing meets Section 16 reporting requirements and contains no additional commentary or unusual provisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

On 2 July 2025, Enstar Group Limited (“Enstar”) filed seven Post-Effective Amendments to Form S-8 registration statements to deregister all unsold ordinary shares that had been reserved for employee and director equity plans. The affected authorisations originally covered approximately 3.16 million ordinary shares across the following programmes:

  • 1,200,000 shares â€� 2006 Equity Incentive Plan (Reg. No. 333-141793)
  • 460,949 shares â€� 1997 Omnibus Incentive Plan and 29,422 shares â€� 2001 Outside Directors Stock Option Plan (Reg. No. 333-148862)
  • 97,862 shares â€� Deferred Compensation Plan for Non-Employee Directors (Reg. No. 333-148863)
  • 200,000 shares â€� Employee Share Purchase Plan (Reg. No. 333-149551)
  • 689,654 shares â€� 2016 Equity Incentive Plan (Reg. No. 333-212131)
  • 84,370 shares â€� A&R 2016 Equity Incentive Plan (Reg. No. 333-237259)
  • 400,000 shares â€� A&R 2016 Equity Incentive Plan (Reg. No. 333-265567)

The amendments were triggered by the completion of a merger agreement dated 29 July 2024 under which Enstar survived a series of transactions and became a wholly-owned subsidiary of Elk Bidco Limited. As no further public issuances will occur, Enstar is terminating the effectiveness of the S-8 registrations in accordance with undertakings contained in each filing. The submission is administrative and contains no new financial results. The document was signed in Hamilton, Bermuda by General Counsel Audrey B. Taranto.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Confluent, Inc. (CFLT) � Form 144 Notice of Proposed Sale

On 07/02/2025 an affiliate of Confluent filed a Form 144 indicating the intention to sell up to 242,501 common shares, representing roughly 0.07 % of the company’s 340,389,876 shares outstanding. The planned broker is Morgan Stanley Smith Barney LLC, Executive Financial Services, New York. Based on the market price used in the filing, the prospective sale is valued at $6.23 million.

The shares were acquired the same day (07/02/2025) via a stock-option exercise, with cash used to cover the exercise price. The filer—identified in prior sales data within the notice as Melanie Vinson—has sold stock in two prior transactions during the last three months: 13,937 shares on 05/22/2025 for $304,662.82 and 14,087 shares on 05/20/2025 for $307,476.95, together totaling 28,024 shares and $612,140 in gross proceeds.

Key takeaways for investors

  • Form 144 filings announce a proposedâ€�not yet executed—sale; actual sales may differ.
  • The number of shares is immaterial to the company’s float but notable for tracking insider sentiment.
  • The stock-option exercise increases the share count by an equal amount, but the dilution impact is de-minimis at the company level.

While the filing signals insider intent to monetize holdings, the relatively small percentage of outstanding shares suggests limited direct market impact. No undisclosed adverse information was asserted by the filer, as required by Rule 144.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Lionsgate Studios Corp. (LION) â€� Form 4 insider filing: Chief Operating Officer Brian Goldsmith reported four equity transactions dated 1 July 2025.

  • Equity grant: 256,024 common shares were awarded at $0 cost (85 % of the target annual equity award under his employment agreement).
  • Performance-based vesting: 46,148 common shares were issued upon vesting of 75 % of previously granted performance RSUs.
  • Tax withholding: To satisfy statutory tax obligations, the issuer automatically canceled 31,245 shares at $5.81 and 23,434 shares at $5.76 (coded “Fâ€�).
  • Post-transaction ownership: Goldsmith now directly holds 1,528,026 common shares, including multiple layers of unvested RSUs scheduled to vest through 2028.

The filing reflects continued equity-based compensation and insider alignment but does not involve open-market buying or selling beyond tax-related cancellations. No derivative securities were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Qualcomm Inc. (QCOM) Form 144 filing discloses that an insider, Akash Palkhiwala, has notified the SEC of an intent to sell 3,333 common shares on or about 07/02/2025 through Goldman Sachs & Co. LLC. The shares have an estimated aggregate market value of $541,012.56, representing roughly 0.0003% of the company’s 1.098 billion outstanding shares.

The filing also details recent activity: over the past three months the same insider sold 9,999 shares across six transactions, generating ~$1.40 million in gross proceeds at prices consistent with market levels. All shares referenced were originally acquired on 09/23/2021 as restricted stock awards granted by the issuer and are being liquidated under Rule 144.

No additional financial metrics, corporate developments or 10b5-1 plan details are provided. Because the contemplated sale is immaterial relative to total shares outstanding and involves previously disclosed compensation stock, the filing is regarded as a routine insider-selling notice rather than a signal of fundamental change at Qualcomm.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Zscaler, Inc. (ZS) has filed a Form 144 indicating a proposed insider sale of common stock. The filing covers the potential sale of 56,428 shares with an aggregate market value of approximately $17.45 million. The shares are expected to be sold on or about 07/02/2025 through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. As disclosed, Zscaler has 155,695,672 shares outstanding; therefore, the planned sale represents roughly 0.036 % of total shares.

The seller, Remo E. Canessa, previously sold 3,684 shares on 06/17/2025 for gross proceeds of $1.12 million. The current Form 144 aggregates shares acquired via restricted stock awards, performance shares, and an employee stock-purchase plan between 2018-2022. No gifts were involved and prior purchases were made either without cash consideration (share grants) or with cash (ESPP shares).

Form 144 is a notice of intent; it does not guarantee that the sale will occur, but it signals insider intent and allows the market to anticipate potential share supply. The filer attests that no material non-public adverse information is known and acknowledges Rule 144 and 10b5-1 representations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Universal Display Corp. (OLED) â€� Form 4 filing dated 07/02/2025

Director Sidney D. Rosenblatt reported the acquisition of 342 shares of OLED common stock on 06/30/2025. The transaction is coded “A� (acquisition) at a stated price of $0, implying the shares were received without cash consideration (e.g., grant or award). Following the transaction, the director’s direct ownership stands at 136,616 shares. In addition, he holds 2,830 shares indirectly via a Grantor Retained Annuity Trust and 17,499 shares through his spouse.

The purchase increases Rosenblatt’s direct stake by less than 0.3%, leaving his overall beneficial ownership essentially unchanged in percentage terms relative to Universal Display’s outstanding share count. Because of the small size and zero-dollar consideration, the filing is unlikely to be financially material, but it does reinforce continued insider alignment with shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary

On 26 June 2025, Incyte Corporation (NASDAQ: INCY) filed a Form 4 reporting an insider transaction by Chief Executive Officer and Director William Meury. The filing discloses a grant of 110,630 employee stock options with an exercise price of $70.81 per share. The options vest 25 % after one year, with the remaining 75 % vesting in equal monthly installments over the subsequent three years, and expire on 25 June 2035. After this grant, Meury beneficially owns 110,630 derivative securities, held directly. No purchases or sales of common stock were reported, and the transaction is classified as "A" (acquisition). The document was signed on 30 June 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Worthington Steel, Inc. (WS) filed a Form 4 reporting that non-employee director Mark C. Davis received an annual equity award of 1,107 restricted common shares on 06/27/2025 under the company’s 2023 Equity Incentive Plan for Non-Employee Directors. The award was granted at $0 cost and will vest at the next Annual Meeting provided Mr. Davis remains on the Board. Following the grant, his direct beneficial ownership increased to 15,383 common shares. No derivative securities were involved and no shares were disposed of. The filing was signed by attorney-in-fact Joseph Y. Heuer on 06/30/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Incyte (INCY)?

The current stock price of Incyte (INCY) is $68.17 as of July 2, 2025.

What is the market cap of Incyte (INCY)?

The market cap of Incyte (INCY) is approximately 13.1B.

What is Incyte Corp's primary focus?

Incyte Corp is primarily focused on the discovery, development, and commercialization of innovative small-molecule therapeutics, with a strong emphasis on oncology and dermatology.

How does Incyte generate revenue?

Incyte generates revenue through the commercialization of its proprietary therapeutics and strategic partnerships with major pharmaceutical companies, enabling global reach and collaborative development efforts.

What therapeutic areas does Incyte primarily target?

Incyte primarily targets oncology, including rare blood cancers and graft-versus-host disease, as well as autoimmune and dermatological conditions such as atopic dermatitis and vitiligo.

How does Incyte differentiate itself in the competitive biopharmaceutical industry?

Incyte differentiates itself by leveraging deep scientific expertise and innovative small-molecule research, supported by strategic global collaborations that enhance clinical development and market access.

What is unique about Incyte's drug development approach?

Incyte’s approach is characterized by an intensive focus on scientific discovery, extensive clinical trials, and data-driven decision making that ensures its therapies meet rigorous efficacy and safety standards.

Can you explain Incyte's role in addressing unmet medical needs?

By targeting areas with significant unmet medical needs, particularly in oncology and immune-mediated disorders, Incyte develops therapies that fill existing treatment gaps and offer new options for patients.

What are some of the key products in Incyte's portfolio?

Incyte's portfolio includes several notable therapies in oncology and dermatology, such as treatments for rare blood cancers and chronic inflammatory conditions; specific product names are referenced by their therapeutic categories.

What role do strategic partnerships play at Incyte?

Strategic partnerships allow Incyte to collaborate with global pharmaceutical leaders, accelerating clinical development and enhancing the commercial reach of its innovative therapies.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Stock Data

13.08B
188.92M
1.99%
96.76%
3.02%
Biotechnology
Services-commercial Physical & Biological Research
United States
WILMINGTON